Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07875023 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of the Carbohydrate Counting Method on Blood Glucose Regulation, Quality of Life, Urinary Glc4 and Other Biomarkers in Children With GSD1

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of the study is to investigate the effects of carbohydrate counting training-administered to pediatric patients diagnosed with GSD 1a and 1b-on blood glucose regulation, quality of life, urinary glucotetrasaccharide (Glc4) levels, and various biomarkers. The main questions it aims to answer are: * Is there a significant change in the urinary Glc4 parameter of patients diagnosed with GSD1 who employ the carbohydrate counting method? * Does the implementation of the carbohydrate counting method in the diets of patients diagnosed with GSD1 lead to a significant change in their quality of life? * Is there a significant change in the HbA1c (%) levels of patients diagnosed with GSD1 who practice the carbohydrate counting method? * Does the application of the carbohydrate counting method in the diets of patients diagnosed with GSD1 result in a significant change in the frequency of infections? Children aged 2-18 years diagnosed with GSD1 will be monitored for a period of 3 months; during this time, food consumption records and anthropometric measurements will be collected, retrospective analysis of continuous glucose monitoring sensor(CGMS) data will be conducted, and various questionnaires and rating scales will be completed both online and in person.
Trial Details
NCT Number NCT07875023
Lead Sponsor Şükrü Arman AKSOY
Conditions
(from sponsor)		 Glycogen Storage Disease Type I, Glycogen Storage Disease Type IB, Glycogen Storage Disease Type IA
Related terms Glycogen Storage Disease, Glycogen Storage Disease IB, Glycogen Storage Disease Type I, Hepatorenal form of glycogen storage disease
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov